

Los 10 hitos del año en Enfermedades Infecciosas, Microbiología Clínica y VIH

VIH y VHC. Dr. Daniel Podzamczar. *Unidad de VIH y ETS. Servicio de Enfermedades Infecciosas, Hospital Universitario de Bellvitge, Hospitalet de Llobregat, Barcelona.*

1. Squires K, Kityo C, Hodder S, Johnson M, Voronin E, Hagins D, Avihingsanon A, Koenig E, Jiang S, White K, Cheng A, Szwarcberg J, Cao H. Integrase inhibitor versus protease inhibitor based regimen for HIV-1 infected women (WAVES): a randomized, controlled, double-blind, phase 3 study. *Lancet HIV* 2016; **3(9): e410-20.**
2. Gallant JE, Daar ES, Raffi F, Brinson C, Ruane P, DeJesus E, Johnson M, Clumeck N, Osiyemi O, Ward D, Morales-Ramirez J, Yan M, Abram ME, Plummer A, Cheng AK, Rhee MS. Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate given as fixed-dose combinations containing emtricitabine as backbones for treatment of HIV-1 infection in virologically suppressed adults: a randomized, double-blind, active-controlled phase 3 trial. *Lancet HIV* 2016; **3: e158-65.**
3. Sax PE, DeJesus E, Crofoot G, Ward D, Benson P, Dretler R, Mills A, Brinson C, Peloquin J, Wei X, White K, Cheng A, Martin H, Quirk E. Bictegravir versus dolutegravir, each with emtricitabine and tenofovir alafenamide, for initial treatment of HIV-1 infection: a randomized, double-blind, phase 2 trial. *Lancet HIV* 2017; **4: e154-e160**
4. Imaz A, Martinez-Picado J, Niubó J, Kashuba ADM, Ferrer E, Ouchi D, Sykes C, Rozas N, Acerete L, Curto J, Vila A, Podzamczar D. HIV-1-RNA Decay and Dolutegravir Concentrations in Semen of Patients Starting a First Antiretroviral Regimen. *J Infect Dis* 2016; **214(10): 1512-1519.**
5. Alaei K, Paynter CA, Juan SC, Alaei A. Using preexposure prophylaxis, losing condoms? Preexposure prophylaxis promotion may undermine safe sex. *AIDS* 2016; **30: 2753-2756.**
6. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N, Hakim JG, Kumwenda J, Grinsztejn B, Pilotto JHS, Godbole SV, Chariyalertsak S, Santos BR, Mayer KH, Hoffman IF, Eshleman SH, Piwowar-Manning E, Cottle L, Zhang XC, Makhema J, Mills LA, Panchia R, Faesen S, Eron J, Gallant J, Havlir D, Swindells S, Elharrar V, Burns D, Taha TE, Nielsen-Saines K, Celentano DD, Essex M, Hudelson SE, Redd AD and Fleming TR, for the HPTN 052 Study Team. Antiretroviral Therapy for the Prevention of HIV-1 Transmission. *N Engl J Med* 2016; **375: 830-839.**

7. Massud I, Mitchell J, Babusis D, Deyoungs F, Ray AS, Rooney JF, Heneine W, Miller MD, García-Lerma JG. Chemoprophylaxis With Oral Emtricitabine and Tenofovir Alafenamide Combination protects Macaques From Rectal Simian/Human Immunodeficiency Virus Infection. *J Infect Dis* 2016; 214: 1058-1062.
8. Borges HA, Neuhaus J, Babiker AG, Henry K, Jain MK, Palfreeman A, Mugenyi P, Domingo P, Hoffman C, Read TRH, Pujari S, Meulbroek M, Johnson M, Wilkin T and Mitsuyasu R for the INSIGHT START Study Group. Immediate antiretroviral therapy reduces risk of infection-related cancer during early HIV infection. *Clin Infect Dis* 2016; 63: 1668-1676.
9. Sereti I, Krebs SJ, Phanuphak N, Fletcher JL, Slike B, Pinyakorn S, O'Connell RJ, Rupert A, Chomont N, Valcour V, Kim JH, Robb ML, Michael NL, Douek DC, Ananworanich J and Uday NS for the RV254/SEARCH 010, RV304/SEARCH 013 and SEARCH 011 protocol teams. Persistent, Albeit Reduced, Chronic Inflammation in Persons Starting Antiretroviral Therapy in Acute HIV Infection. *Clin Infect Dis* 2017; 64: 124-131.
10. Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison J, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X for the SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomized, phase 2 trial. *Lancet Infect Dis* 2016; 16: 685-697.
11. Gane E, Poordad F, Wang S, Asatryan A, Kwo PY, Lalezar J, Wyles DL, Hassanein T, Aguilar H, Maliakkal B, Liu R, Lin CW, Ng TI, Kort J, Mensa FJ. High Efficacy of ABT-493 and ABT-530 Treatment in Patients With HCV Genotype 1 or 3 Infection and Compensated Cirrhosis. *Gastroenterology* 2016; 151: 651-659